Related references
Note: Only part of the references are listed.Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
Michael Bonelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Arabella S. Stuart et al.
LANCET (2022)
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
Thiago Cerqueira-Silva et al.
NATURE MEDICINE (2022)
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng et al.
NATURE MEDICINE (2022)
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Shirley Collie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Lisa M. Dunkle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
J. Sadoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Rolando Pajon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
E. B. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
S. M. Olson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review
Ibrahim Mohammed et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden
Jonas Bjork et al.
INFECTIOUS DISEASES (2022)
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
Anne M. Hause et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population
Adeel A. Butt et al.
CLINICAL INFECTIOUS DISEASES (2022)
A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine
Lei Yue et al.
JOURNAL OF MEDICAL VIROLOGY (2022)
Efficiency decreases
Halane Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study
Devashish Desai et al.
LANCET INFECTIOUS DISEASES (2022)
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
Yinon M. Bar-On et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Ori Magen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Eduardo Hermosilla et al.
NATURE COMMUNICATIONS (2022)
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
Sara Y. Tartof et al.
LANCET REGIONAL HEALTH-AMERICAS (2022)
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
Thiago Cerqueira-Silva et al.
LANCET REGIONAL HEALTH-AMERICAS (2022)
Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
Katia J. Bruxvoort et al.
LANCET REGIONAL HEALTH-AMERICAS (2022)
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin et al.
LANCET (2022)
Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021
Dan Wu et al.
CHINA CDC WEEKLY (2022)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021
Ivan Martinez-Baz et al.
EUROSURVEILLANCE (2021)
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Raches Ella et al.
LANCET (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof et al.
LANCET (2021)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda et al.
LANCET (2021)
Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
Ben Y. Reis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
Victoria Rotshild et al.
SCIENTIFIC REPORTS (2021)
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
Katia J. Bruxvoort et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data
Aharona Glatman-Freedman et al.
EBIOMEDICINE (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary et al.
LANCET (2021)
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination
Nan-Chang Chiu et al.
EXPERT REVIEW OF VACCINES (2021)
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
Nawal Al Kaabi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
Marie Tre-Hardy et al.
JOURNAL OF INFECTION (2021)
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
Mine Durusu Tanriover et al.
LANCET (2021)
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri et al.
LANCET INFECTIOUS DISEASES (2021)
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Kashif Ali et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W. Frenck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Paul T. Heath et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
Peter Nordstrom et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Evaluating the Quality of Evidence from a Network Meta-Analysis
Georgia Salanti et al.
PLOS ONE (2014)
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
Milo A. Puhan et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Incorporating data from various trial designs into a mixed treatment comparison model
Susanne Schmitz et al.
STATISTICS IN MEDICINE (2013)